Promoting the adoption of local governmental policy on the reimbursement of chronic disease medicines (PAPMed): study protocol of a field-based cluster randomized trial in rural Nantong, China.
Behavior science
China
Cluster randomized trial
Medication reimbursement policy
Non-communicable disease
Rural health
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
15 Sep 2022
15 Sep 2022
Historique:
received:
19
07
2021
accepted:
02
09
2022
entrez:
15
9
2022
pubmed:
16
9
2022
medline:
20
9
2022
Statut:
epublish
Résumé
Among rural Chinese patients with non-communicable diseases (NCDs), low socioeconomic status increases the risk of developing NCDs and associated financial burdens in paying for medicines and treatments. Despite the chronic disease medicine reimbursement policy of the local government in Nantong City, China, various barriers prevent patients from registering for and benefitting from the policy. This study aims to develop a behavior science-based intervention program for promoting the adoption of the policy and to evaluate the effectiveness of the program compared with usual practices. Barriers and opportunities affecting stakeholders in adopting the policy were identified through contextual research and summarized through behavior mapping. The intervention is designed to target these barriers and opportunities through behavior science theories and will be evaluated through a 6-month cluster randomized controlled trial in Tongzhou District, Nantong, China. A total of 30 villages from two townships are randomized in a 1:1 ratio to either the intervention or the control arm (usual practices). Village doctors in the intervention arm (1) receive systematic training on policy details, registration procedures, and intervention protocol, (2) promote the policy and encourage registration, (3) follow up with patients in the first, third, and sixth months after the intervention, and (4) receive financial incentives based on performance. The primary outcome is policy registration rate and the secondary outcomes include the number of patients registering for the policy, medical costs saved, frequency of village doctor visits, and health measures such as blood pressure and glucose levels. This study is one of very few that aims to promote adoption of NCDs outpatient medication reimbursement policies, and the first study to evaluate the impact of these policies on patients' financial and physical wellbeing in China. The simple, feasible, and scalable intervention is designed based on the theories of behavior science and is applicable to similar low-income regions nationwide where outpatient medical costs remain a financial burden for patients. ClinicalTrials.gov NCT04731194 , registered on 29 January 2021; Chinese Clinical Trial Registry ChiCTR2100042152 , registered on 14 January 14 2021.
Sections du résumé
BACKGROUND
BACKGROUND
Among rural Chinese patients with non-communicable diseases (NCDs), low socioeconomic status increases the risk of developing NCDs and associated financial burdens in paying for medicines and treatments. Despite the chronic disease medicine reimbursement policy of the local government in Nantong City, China, various barriers prevent patients from registering for and benefitting from the policy. This study aims to develop a behavior science-based intervention program for promoting the adoption of the policy and to evaluate the effectiveness of the program compared with usual practices.
METHODS
METHODS
Barriers and opportunities affecting stakeholders in adopting the policy were identified through contextual research and summarized through behavior mapping. The intervention is designed to target these barriers and opportunities through behavior science theories and will be evaluated through a 6-month cluster randomized controlled trial in Tongzhou District, Nantong, China. A total of 30 villages from two townships are randomized in a 1:1 ratio to either the intervention or the control arm (usual practices). Village doctors in the intervention arm (1) receive systematic training on policy details, registration procedures, and intervention protocol, (2) promote the policy and encourage registration, (3) follow up with patients in the first, third, and sixth months after the intervention, and (4) receive financial incentives based on performance. The primary outcome is policy registration rate and the secondary outcomes include the number of patients registering for the policy, medical costs saved, frequency of village doctor visits, and health measures such as blood pressure and glucose levels.
DISCUSSION
CONCLUSIONS
This study is one of very few that aims to promote adoption of NCDs outpatient medication reimbursement policies, and the first study to evaluate the impact of these policies on patients' financial and physical wellbeing in China. The simple, feasible, and scalable intervention is designed based on the theories of behavior science and is applicable to similar low-income regions nationwide where outpatient medical costs remain a financial burden for patients.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov NCT04731194 , registered on 29 January 2021; Chinese Clinical Trial Registry ChiCTR2100042152 , registered on 14 January 14 2021.
Identifiants
pubmed: 36109757
doi: 10.1186/s13063-022-06710-1
pii: 10.1186/s13063-022-06710-1
pmc: PMC9479297
doi:
Substances chimiques
Glucose
IY9XDZ35W2
Banques de données
ClinicalTrials.gov
['NCT04731194']
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
785Informations de copyright
© 2022. The Author(s).
Références
Biometrics. 1986 Mar;42(1):121-30
pubmed: 3719049
Med J Aust. 2003 Oct 20;179(8):438-40
pubmed: 14558871
Infect Dis Poverty. 2013 Apr 05;2(1):7
pubmed: 23849054
Lancet. 2019 Sep 28;394(10204):1145-1158
pubmed: 31248666
Stat Methods Med Res. 2013 Dec;22(6):661-70
pubmed: 22072596
BMJ. 2017 Jul 14;358:j3064
pubmed: 28710062
Clin Epidemiol. 2019 Sep 03;11:801-820
pubmed: 31564985
Soc Sci Med. 2009 Jan;68(2):201-9
pubmed: 19019519
Health Policy. 2019 Dec;123(12):1210-1220
pubmed: 31587819
Lancet. 2005 Nov 19;366(9499):1821-4
pubmed: 16298221
Mar Pollut Bull. 2019 Jul;144:48-60
pubmed: 31180006
Diabetes Metab. 2020 Nov;46(6):450-460
pubmed: 32387700
Lancet. 2008 Sep 13;372(9642):940-9
pubmed: 18790317
Circulation. 2015 Sep 1;132(9):815-24
pubmed: 26187183
Health Educ Behav. 2017 Apr;44(2):245-253
pubmed: 27226430
Lancet. 2013 Jun 8;381(9882):1987-2015
pubmed: 23746901
Int J Environ Res Public Health. 2018 Oct 26;15(11):
pubmed: 30373205
Anesthesiology. 2019 Jan;130(1):154-170
pubmed: 30074931
BMJ. 2020 Apr 28;369:m997
pubmed: 32345662
Chronic Dis Transl Med. 2015 Aug 24;1(3):133-140
pubmed: 29062998
N C Med J. 2016 Jul-Aug;77(4):265-8
pubmed: 27422948
J Epidemiol. 2020 Aug 5;30(8):354-361
pubmed: 31327817
Public Health. 2012 Mar;126(3):210-213
pubmed: 22325671
BMC Public Health. 2019 Aug 07;19(1):1059
pubmed: 31391010
BMC Public Health. 2017 Dec 12;17(1):947
pubmed: 29233114
BMJ. 2013 Jan 08;346:e7586
pubmed: 23303884
Glob Public Health. 2020 Apr;15(4):611-625
pubmed: 31630629
Lancet. 2017 Dec 9;390(10112):2584-2594
pubmed: 29231837
Am J Epidemiol. 2003 Feb 15;157(4):364-75
pubmed: 12578807
BMC Health Serv Res. 2018 Nov 20;18(1):871
pubmed: 30458772
Ann Intern Med. 2013 Feb 5;158(3):200-7
pubmed: 23295957
J Hypertens. 2016 Jan;34(1):39-46
pubmed: 26630211
PLoS Med. 2021 Apr 28;18(4):e1003582
pubmed: 33909607
JMIR Hum Factors. 2020 Sep 17;7(3):e17416
pubmed: 32940610
BMC Med Res Methodol. 2011 Jun 30;11:102
pubmed: 21718530
Lancet. 2017 Dec 9;390(10112):2549-2558
pubmed: 29102084
Int J Equity Health. 2009 Dec 09;8:42
pubmed: 20003188